This federal contract award is for the delivery of Pulmozyme, a pharmaceutical product used in the treatment of cystic fibrosis, to the Defense Logistics Agency (DLA). The $14,822.52 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract has a period of performance through December 13, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order is a call against that larger IDC contract.
Generated 3/13/25, 9:47 AM